{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,11]],"date-time":"2024-08-11T00:24:13Z","timestamp":1723335853301},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology and Applied Pharmacology"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.taap.2024.117021","type":"journal-article","created":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T17:32:57Z","timestamp":1720114377000},"page":"117021","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["In vitro study on the anticancer effects of oxalipalladium against PC3 human prostate carcinoma cells"],"prefix":"10.1016","volume":"490","author":[{"given":"Zahra","family":"Fathi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Armen","family":"Avanes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zohreh","family":"Jahanafrooz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.taap.2024.117021_bb0005","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3747\/co.v18i1.708","article-title":"Oxaliplatin: a review in the era of molecularly targeted therapy","volume":"18","author":"Alcindor","year":"2011","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.taap.2024.117021_bb0010","doi-asserted-by":"crossref","first-page":"4948","DOI":"10.1016\/j.bmc.2014.06.039","article-title":"Apoptosis-inducing effect of a palladium (II) saccharinate complex of terpyridine on human breast cancer cells in vitro and in vivo","volume":"22","author":"Ari","year":"2014","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.taap.2024.117021_bb0015","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ica.2016.02.053","article-title":"DNA binding, topoisomerase inhibition and cytotoxicity of palladium (II) complexes with 1, 10-phenanthroline and thioureas","volume":"446","author":"Barra","year":"2016","journal-title":"Inorg. Chim. Acta"},{"key":"10.1016\/j.taap.2024.117021_bb0020","doi-asserted-by":"crossref","first-page":"4501","DOI":"10.1021\/bi702019z","article-title":"Substituents on etoposide that interact with human topoisomerase II\u03b1 in the binary enzyme\u2212 drug complex: contributions to etoposide binding and activity","volume":"47","author":"Bender","year":"2008","journal-title":"Biochemistry"},{"key":"10.1016\/j.taap.2024.117021_bb0025","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/4993405","article-title":"Cytotoxic action of palladium-based compound on prostate stem cells, primary prostate epithelial cells, prostate epithelial cells, and prostate cell lines","volume":"2022","author":"Cheng","year":"2022","journal-title":"J. Healthc. Eng."},{"key":"10.1016\/j.taap.2024.117021_bb0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-020-00943-w","article-title":"ETV4 promotes late development of prostatic intraepithelial neoplasia and cell proliferation through direct and p53-mediated downregulation of p21","volume":"13","author":"Cosi","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.taap.2024.117021_bb0035","doi-asserted-by":"crossref","first-page":"14279","DOI":"10.1039\/C9DT02873K","article-title":"Water soluble, optically active monofunctional Pd (II) and Pt (II) compounds: promising adhesive and antimigratory effects on human prostate PC-3 cancer cells","volume":"48","author":"de la Cueva-Alique","year":"2019","journal-title":"Dalton Trans."},{"key":"10.1016\/j.taap.2024.117021_bb0040","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.saa.2013.09.126","article-title":"Spectroscopic and theoretical investigation of oxali\u2013palladium interactions with \u03b2-lactoglobulin","volume":"118","author":"Ghalandari","year":"2014","journal-title":"Spectrochim. Acta A Mol. Biomol. Spectrosc."},{"key":"10.1016\/j.taap.2024.117021_bb0045","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1007\/s12010-014-1341-0","article-title":"Probing of the interaction between \u03b2-lactoglobulin and the anticancer drug oxaliplatin","volume":"175","author":"Ghalandari","year":"2015","journal-title":"Appl. Biochem. Biotechnol."},{"key":"10.1016\/j.taap.2024.117021_bb0050","doi-asserted-by":"crossref","first-page":"357","DOI":"10.3390\/antiox9040357","article-title":"Melatonin enhances palladium-nanoparticle-induced cytotoxicity and apoptosis in human lung epithelial adenocarcinoma cells A549 and H1229","volume":"9","author":"Gurunathan","year":"2020","journal-title":"Antioxidants"},{"key":"10.1016\/j.taap.2024.117021_bb0055","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/j.ejmech.2005.06.003","article-title":"Synthesis and structure-activity relationships of mono-and dialkyl-substituted oxaliplatin derivatives","volume":"40","author":"Habala","year":"2005","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.taap.2024.117021_bb0060","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1002\/bem.22072","article-title":"Stable morphological\u2013physiological and neural protein expression changes in rat bone marrow mesenchymal stem cells treated with electromagnetic field and nitric oxide","volume":"38","author":"Haghighat","year":"2017","journal-title":"Bioelectromagnetics"},{"key":"10.1016\/j.taap.2024.117021_bb0065","doi-asserted-by":"crossref","first-page":"115573","DOI":"10.1016\/j.taap.2021.115573","article-title":"Delivery of oxaliplatin to colorectal cancer cells by folate-targeted UiO-66-NH2","volume":"423","author":"Hashemzadeh","year":"2021","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.taap.2024.117021_bb0070","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1124\/mol.104.004416","article-title":"Biochemical and proteomics approaches to characterize topoisomerase II\u03b1 cysteines and DNA as targets responsible for cisplatin-induced inhibition of topoisomerase II\u03b1","volume":"67","author":"Hasinoff","year":"2005","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.taap.2024.117021_bb0075","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.apsb.2018.07.008","article-title":"Recent developments in topoisomerase-targeted cancer chemotherapy","volume":"8","author":"Hevener","year":"2018","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.taap.2024.117021_bb0080","doi-asserted-by":"crossref","first-page":"12483","DOI":"10.1093\/nar\/gkaa1002","article-title":"A unified model for the G1\/S cell cycle transition","volume":"48","author":"Hume","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.taap.2024.117021_bb0085","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jpba.2012.08.010","article-title":"A full validated hydrophilic interaction liquid chromatography\u2013tandem mass spectrometric method for the quantification of oxaliplatin in human plasma ultrafiltrates","volume":"71","author":"Ito","year":"2012","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.taap.2024.117021_bb0090","doi-asserted-by":"crossref","first-page":"4153","DOI":"10.1002\/jcp.29337","article-title":"Colon cancer therapy by focusing on colon cancer stem cells and their tumor microenvironment","volume":"235","author":"Jahanafrooz","year":"2020","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.taap.2024.117021_bb0095","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1038\/s41388-018-0555-y","article-title":"Tissue necrosis and its role in cancer progression","volume":"38","author":"Karsch-Bluman","year":"2019","journal-title":"Oncogene"},{"key":"10.1016\/j.taap.2024.117021_bb0100","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.3390\/ijms24031888","article-title":"Evaluation of the cytotoxic effect of Pd2Spm against prostate Cancer through vibrational microspectroscopies","volume":"24","author":"Laginha","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.taap.2024.117021_bb0105","doi-asserted-by":"crossref","first-page":"859","DOI":"10.3390\/genes10110859","article-title":"Cell cycle-dependent control and roles of DNA topoisomerase II","volume":"10","author":"Lee","year":"2019","journal-title":"Genes"},{"key":"10.1016\/j.taap.2024.117021_bb0110","doi-asserted-by":"crossref","first-page":"204","DOI":"10.3390\/md16060204","article-title":"Heteronemin, a marine Sesterterpenoid-type metabolite, induces apoptosis in prostate LNcap cells via oxidative and ER stress combined with the inhibition of topoisomerase II and Hsp90","volume":"16","author":"Lee","year":"2018","journal-title":"Mar. Drugs"},{"key":"10.1016\/j.taap.2024.117021_bb0115","doi-asserted-by":"crossref","first-page":"964","DOI":"10.3390\/molecules27030964","article-title":"Synthesis, characterization, thermal analysis, DFT, and cytotoxicity of palladium complexes with nitrogen-donor ligands","volume":"27","author":"Majeed","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.taap.2024.117021_bb0120","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1111\/j.1464-410X.2008.07512.x","article-title":"Leptin and adiponectin interact in the regulation of prostate cancer cell growth via modulation of p53 and bcl-2 expression","volume":"101","author":"Mistry","year":"2008","journal-title":"BJU Int."},{"key":"10.1016\/j.taap.2024.117021_bb0125","doi-asserted-by":"crossref","first-page":"106477","DOI":"10.1016\/j.ejps.2023.106477","article-title":"High cancer selectivity and improving drug release from mesoporous silica nanoparticles in the presence of human serum albumin in cisplatin, carboplatin, oxaliplatin, and oxalipalladium treatment","volume":"187","author":"Moghadam","year":"2023","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.taap.2024.117021_bb0130","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.21873\/anticanres.16408","article-title":"Improved analysis of prostate Cancer: VIM3, ATG7 and P53 form a complex and activate miRNA 371a-3p","volume":"43","author":"Nohl","year":"2023","journal-title":"Anticancer Res."},{"key":"10.1016\/j.taap.2024.117021_bb0135","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jpba.2018.03.045","article-title":"Hydrophilic interaction liquid chromatography-tandem mass spectrometry method for the determination of intact oxaliplatin in cells: validated and applied in colon cancer HCT-116 cell line","volume":"155","author":"Qin","year":"2018","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.taap.2024.117021_bb0140","article-title":"Cationic Pd (II) complexes acting as topoisomerase II inhibitors: synthesis, characterization, DNA interaction and cytotoxicity","volume":"165-168","author":"Rocha","year":"2016","journal-title":"J. Inorg. Biochem."},{"key":"10.1016\/j.taap.2024.117021_bb0145","doi-asserted-by":"crossref","first-page":"462","DOI":"10.15171\/apb.2019.055","article-title":"Synergetic impact of combined 5-fluorouracil and rutin on apoptosis in pc3 cancer cells through the modulation of p53 gene expression","volume":"9","author":"Satari","year":"2019","journal-title":"Adv Pharm Bull"},{"key":"10.1016\/j.taap.2024.117021_bb0150","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0142327","article-title":"Topoisomerase 2 alpha cooperates with androgen receptor to contribute to prostate cancer progression","volume":"10","author":"Schaefer-Klein","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.taap.2024.117021_bb0155","article-title":"Differential cytotoxic activity of a novel palladium-based compound on prostate cell lines, primary prostate epithelial cells and prostate stem cells","volume":"5","author":"Ulukaya","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.taap.2024.117021_bb0160","doi-asserted-by":"crossref","first-page":"8929","DOI":"10.1039\/C7DT01628J","article-title":"Oxaliplatin reacts with DMSO only in the presence of water","volume":"46","author":"Varbanov","year":"2017","journal-title":"Dalton Trans."},{"key":"10.1016\/j.taap.2024.117021_bb0165","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/nrm3228","article-title":"All tangled up: how cells direct, manage and exploit topoisomerase function","volume":"12","author":"Vos","year":"2011","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.taap.2024.117021_bb0170","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/4277254","article-title":"DNA topoisomerase II-\u03b1 regulated by miR-22-5p promotes hepatocellular carcinoma invasion and migration through the hippo pathway","volume":"2022","author":"Zhao","year":"2022","journal-title":"Oxidative Med. Cell. Longev."}],"container-title":["Toxicology and Applied Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X24002199?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X24002199?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,10]],"date-time":"2024-08-10T23:25:34Z","timestamp":1723332334000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041008X24002199"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":34,"alternative-id":["S0041008X24002199"],"URL":"https:\/\/doi.org\/10.1016\/j.taap.2024.117021","relation":{},"ISSN":["0041-008X"],"issn-type":[{"type":"print","value":"0041-008X"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro study on the anticancer effects of oxalipalladium against PC3 human prostate carcinoma cells","name":"articletitle","label":"Article Title"},{"value":"Toxicology and Applied Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.taap.2024.117021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117021"}}